PSI 5004
Alternative Names: PSI-5004; Racemic FTC; Racivir; RCV - PharmassetLatest Information Update: 31 Jan 2012
At a glance
- Originator Emory University
- Developer Pharmasset
- Class Antivirals; Dideoxynucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - HIV infections
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 31 Jan 2012 No development reported - Phase-II for HIV infections in Argentina (PO)
- 31 Jan 2012 No development reported - Phase-II for HIV infections in Mexico (PO)
- 31 Jan 2012 No development reported - Phase-II for HIV infections in Panama (PO)